Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P69905

UPID:
HBA_HUMAN

ALTERNATIVE NAMES:
Alpha-globin; Hemoglobin alpha chain

ALTERNATIVE UPACC:
P69905; P01922; Q1HDT5; Q3MIF5; Q53F97; Q96KF1; Q9NYR7; Q9UCM0

BACKGROUND:
The Hemoglobin subunit alpha, or Alpha-globin, is integral to the body's oxygen transport mechanism, highlighting its importance in sustaining life. The protein's function extends to inhibiting the cannabinoid receptor CNR1 through Hemopressin, showcasing its potential in modulating physiological responses beyond oxygen transport.

THERAPEUTIC SIGNIFICANCE:
Variants affecting the Hemoglobin subunit alpha gene lead to serious blood disorders such as Heinz body anemias, Alpha-thalassemia, and Hemoglobin H disease. These conditions underscore the protein's therapeutic significance, as advancements in understanding its role could pave the way for innovative treatments, including gene editing techniques and novel drug therapies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.